Medscape: tirzepatide shows early then plateau

Medscape reported on May 22 that new modeling data linked tirzepatide to strong early weight loss followed by a later plateau in appetite and energy-balance measures. The publication said the model showed appetite suppression easing over time while energy expenditure declined, a pattern that tracked with slowing weight loss. Medscape also reported that stopping tirzepatide in the model led to partial weight regain. In separate May 22 coverage, the outlet said semaglutide and tirzepatide were associated with one-year weight loss in real-world rheumatology care, with larger losses among tirzepatide users. ### What did the tirzepatide modeling show after the early drop? Medscape said the modeling found “marked early weight loss” with tirzepatide before the effect leveled off later in treatment. The reported mechanism in the model was twofold: appetite gradually returned and energy expenditure decreased, reducing the pace of additional loss over time. The same Medscape item said the plateau should not be read as a sudden failure of the drug. (medscape.com) A separate Medscape commentary published April 8 described weight-loss plateaus as a common and expected phase of obesity treatment, with physician Beverly Tchang saying patients often experience them even when they are adhering to treatment. ### What happened in the model when treatment stopped? Medscape reported that discontinuing tirzepatide produced partial weight regain in the modeling. The article, as summarized in Medscape’s index, tied that regain to the same energy-balance dynamics that had shifted during treatment, rather than presenting maintenance as automatic after discontinuation. Medscape’s broader May coverage has also focused on what happens after dose changes or treatment adjustments. (medscape.com) An obesity news index item published May 19 highlighted trial data asking whether lower-dose tirzepatide can help some patients maintain meaningful weight loss after stepping down from the maximum dose. ### What did the real-world rheumatology report add? Medscape reported on May 22 that semaglutide and tirzepatide use is rising among patients with rheumatic and musculoskeletal diseases and is linked to meaningful one-year weight loss in routine care. (medscape.com) The report said the larger reductions were seen in tirzepatide users. That real-world report matters because it sits alongside the modeling story rather than replacing it. (medscape.com) The modeling described the shape of weight change over time, while the rheumatology report described observed one-year outcomes in clinical practice, according to Medscape’s summaries. ### Why were clinicians also talking about plateaus and monitoring? Medscape’s May 22 and April obesity coverage put plateaus in a clinical-management frame, not just a patient-expectation frame. (medscape.com) Tchang wrote in the April 8 commentary that plateaus are normal and that clinicians should help patients navigate them rather than treat them as proof that therapy has stopped working. (medscape.com) Medscape has also published broader arguments for more structured GLP-1 care. In a March commentary on prescribing practices, the outlet described better outcomes in a comprehensive care model with individualized follow-up and ongoing support, rather than a standalone prescription approach. ### Where does this leave the current Medscape thread on GLP-1 treatment? (medscape.com) Medscape’s recent obesity coverage now points in three directions at once: early response can be strong, plateaus can emerge later, and longer-term outcomes depend on what happens during continued care or after dose changes. The outlet’s May 22 reporting paired the tirzepatide modeling with a separate real-world cohort story and with existing physician guidance on managing plateaus. (medscape.com) Medscape’s obesity and internal medicine indexes remain the next place to watch for follow-up items on tirzepatide dosing, plateau management and post-discontinuation weight maintenance, including additional ECO 2026 coverage and related GLP-1 reports. (medscape.com 1) (medscape.com 2)